Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Cureus ; 15(3): e36359, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-37082477

RESUMO

Endogenous endophthalmitis occurs in the setting of an intraocular infection secondary to the spread of bacterial, viral, or fungal pathogens with a high likelihood of permanent vision loss if left untreated. This case describes a 33-year-old male with numerous risk factors presenting with sudden onset of symptoms consistent with endogenous endophthalmitis secondary to Streptococcus beta-hemolyticus group G bacteremia of unknown source. He was treated with broad-spectrum antibiotics and analgesics with improvement in symptoms.

2.
J Investig Med High Impact Case Rep ; 10: 23247096221133191, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36300416

RESUMO

Amyloidosis rarely presents as localized lymphadenopathy. Various studies have elucidated the varied presentation and manifestations of this interesting disease. We reviewed the literature and found 36 cases of primary amyloidosis with lymph node enlargement as a presentation, and 17 of the 36 cases (47%) had systemic involvement on further work up. We describe a patient who presented with an isolated right axillary mass. Clinical examination and radiology were indicative of a lymph node enlargement with no evidence of malignancy in the breasts or lungs. Histopathological examination was indicative of amyloidosis. A further work up including serum, urine biochemistry, cardiac work up, bone marrow examination, and a kidney biopsy revealed systemic amyloidosis. Patient was treated with daratumumab and CyBorD (cyclophosphamide, bortezomib, and dexamethasone) followed by a stem cell transplantation. Patient is in remission for 1 year, at the time of submission of this report. Therefore, we conclude (1) systemic amyloidosis presenting as an isolated lymph node enlargement is rare, (2) a structured systemic work up is imperative for early diagnosis and proper management of amyloidosis, when there is an index of suspicion, and (3) use of novel therapeutic options such as CD38 + antibody (daratumumab) and stem cell transplant have positive impact on disease outcomes.


Assuntos
Amiloidose , Amiloidose de Cadeia Leve de Imunoglobulina , Linfadenopatia , Humanos , Amiloidose de Cadeia Leve de Imunoglobulina/complicações , Amiloidose de Cadeia Leve de Imunoglobulina/diagnóstico , Amiloidose de Cadeia Leve de Imunoglobulina/tratamento farmacológico , Bortezomib/uso terapêutico , Amiloidose/complicações , Amiloidose/diagnóstico , Amiloidose/tratamento farmacológico , Linfadenopatia/patologia , Ciclofosfamida/uso terapêutico , Dexametasona/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA